Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
Ann Rheum Dis
; 81(5): 653-661, 2022 05.
Article
in En
| MEDLINE
| ID: mdl-35264321
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Giant Cell Arteritis
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Ann Rheum Dis
Year:
2022
Document type:
Article
Country of publication:
Reino Unido